Hypoxia and drug resistance - PubMed (original) (raw)

Review

Hypoxia and drug resistance

B A Teicher. Cancer Metastasis Rev. 1994 Jun.

Abstract

Biologically and therapeutically important hypoxia occurs in many solid tumor masses. Hypoxia can be a direct cause of therapeutic resistance because some drugs and radiation require oxygen to be maximally cytotoxic. Cellular metabolism is altered under hypoxic conditions. Hypoxia can result in drug resistance indirectly if under this condition cells more effectively detoxify the drug molecules. Finally, there is evidence that hypoxia can enhance genetic instability in tumor cells thus allowing more rapid development of drug resistance cells. The current review describes the effects of hypoxia on tumor response to a variety of anti-cancer agents and also describes progress toward therapeutically useful methods of delivering oxygen to tumors in an effort to overcome therapeutic resistance due to hypoxia. Finally, the use of hypoxic cell selective cytotoxic agents as a means of addressing hypoxic 'drug resistance' is discussed.

PubMed Disclaimer

Similar articles

• In vitro testing of chemosensitivity in physiological hypoxia.
  Grigoryan R, Keshelava N, Anderson C, Reynolds CP. Grigoryan R, et al. Methods Mol Med. 2005;110:87-100. doi: 10.1385/1-59259-869-2:087. Methods Mol Med. 2005. PMID: 15901930
• The Antiproliferative and Colony-suppressive Activities of STAT3 Inhibitors in Human Cancer Cells Is Compromised Under Hypoxic Conditions.
  Tian J, Xiao H, Wu R, Cao Y, Li C, Xu R, Pierson CR, Finlay JL, Yang F, Gu N, Lin J. Tian J, et al. Anticancer Res. 2017 Feb;37(2):547-553. doi: 10.21873/anticanres.11347. Anticancer Res. 2017. PMID: 28179300 Free PMC article.
• Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
  Phillips RM. Phillips RM. Cancer Chemother Pharmacol. 2016 Mar;77(3):441-57. doi: 10.1007/s00280-015-2920-7. Epub 2016 Jan 25. Cancer Chemother Pharmacol. 2016. PMID: 26811177 Free PMC article. Review.
• SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
  Brown JM. Brown JM. Br J Cancer. 1993 Jun;67(6):1163-70. doi: 10.1038/bjc.1993.220. Br J Cancer. 1993. PMID: 8512801 Free PMC article. Review.
• Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
  Ebbesen P, Pettersen EO, Gorr TA, Jobst G, Williams K, Kieninger J, Wenger RH, Pastorekova S, Dubois L, Lambin P, Wouters BG, Van Den Beucken T, Supuran CT, Poellinger L, Ratcliffe P, Kanopka A, Görlach A, Gasmann M, Harris AL, Maxwell P, Scozzafava A. Ebbesen P, et al. J Enzyme Inhib Med Chem. 2009 Apr;24 Suppl 1:1-39. doi: 10.1080/14756360902784425. J Enzyme Inhib Med Chem. 2009. PMID: 19330638 Review.

Cited by

• The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma.
  Li J, Liu H, Li L, Wu H, Wang C, Yan Z, Wang Y, Su C, Jin H, Zhou F, Wu M, Qian Q. Li J, et al. Oncol Rep. 2013 Mar;29(3):895-902. doi: 10.3892/or.2012.2217. Epub 2012 Dec 28. Oncol Rep. 2013. PMID: 23292657 Free PMC article.
• A novel 3D polycaprolactone high-throughput system for evaluation of toxicity in normoxia and hypoxia.
  Malakpour-Permlid A, Oredsson S. Malakpour-Permlid A, et al. Toxicol Rep. 2021 Mar 20;8:627-635. doi: 10.1016/j.toxrep.2021.03.015. eCollection 2021. Toxicol Rep. 2021. PMID: 33854950 Free PMC article.
• Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
  Chintala S, Tóth K, Cao S, Durrani FA, Vaughan MM, Jensen RL, Rustum YM. Chintala S, et al. Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911. doi: 10.1007/s00280-009-1238-8. Epub 2010 Jan 12. Cancer Chemother Pharmacol. 2010. PMID: 20066420 Free PMC article.
• Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy.
  Franceschini D, Paiar F, Saieva C, Bonomo P, Agresti B, Meattini I, Greto D, Mangoni M, Meacci F, Loi M, Zei G, Livi L, Biti G. Franceschini D, et al. Radiol Med. 2016 Mar;121(3):229-37. doi: 10.1007/s11547-015-0586-1. Epub 2015 Sep 24. Radiol Med. 2016. PMID: 26403512
• Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance.
  Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C. Erler JT, et al. Mol Cell Biol. 2004 Apr;24(7):2875-89. doi: 10.1128/MCB.24.7.2875-2889.2004. Mol Cell Biol. 2004. PMID: 15024076 Free PMC article.

References

1. 1. Biochem Pharmacol. 1985 Dec 15;34(24):4191-5 - PubMed
2. 1. J Natl Cancer Inst. 1967 Oct;39(4):639-52 - PubMed
3. 1. Biochem Biophys Res Commun. 1979 Mar 30;87(2):649-53 - PubMed
4. 1. Cancer Res. 1985 Jan;45(1):213-6 - PubMed
5. 1. Cancer Res. 1982 Dec;42(12):4921-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database